z-logo
Premium
Evaluation of carcinoembryonic antigen‐related cell adhesion molecule 1 blood serum levels in women at high risk for preeclampsia
Author(s) -
Mach Pawel,
Andrikos Dimitrios,
Schmidt Boerge,
Gellhaus Alexandra,
Rusch Peter,
Birdir Cahit,
Andrikos Argyrios,
Schmitt Verena,
Kimmig Rainer,
Singer Bernhard B.,
Köninger Angela
Publication year - 2021
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.13375
Subject(s) - medicine , carcinoembryonic antigen , pregnancy , preeclampsia , third trimester , obstetrics , cell adhesion molecule , adhesion , first trimester , gastroenterology , immunology , gestation , biology , chemistry , genetics , organic chemistry , cancer
Abstract Problem The aim of this study was to evaluate the sCEACAM1 concentrations in serum from patients in the first trimester who have a high risk for developing PE during pregnancy. Method of the study Carcinoembryonic antigen‐related cell adhesion molecule 1 (CEACAM1) levels were determined with ELISA. The patients ( n  = 109) were divided into two groups: patients who have a high risk of developing PE early‐onset and a control group. Patients who have a high risk of developing PE were then divided into two subgroups depending on PE development in third trimester of pregnancy: PE in third trimester versus no PE in third trimester. Results sCEACAM1 concentrations in patients who were screened as having a high risk for developing PE were significantly higher than in healthy pregnant women in the first trimester ( p  = .03). The highest sCEACAM1 concentration was found in the high‐risk group with PE development compared to the control group ( p  = .004). Conclusion Elevated sCEACAM1 blood serum levels in women with PE suggest that there is immune dysregulation in early pregnancy, which may be helpful in PE prediction and therapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here